Literature DB >> 19494272

GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo.

Ronald W van Olffen1, Nathalie Koning, Klaas P J M van Gisbergen, Felix M Wensveen, Robert M Hoek, Louis Boon, Jörg Hamann, Rene A W van Lier, Martijn A Nolte.   

Abstract

Glucocorticoid-induced TNF receptor family-related protein (GITR) is expressed on activated and regulatory T cells, but its role on these functionally opposing cell types is not fully understood. Here we describe that transgenic expression of GITR's unique ligand (GITRL) induces a prominent increase of both effector and regulatory CD4(+) T cells, but not CD8(+) T cells. Regulatory T cells from GITRL transgenic mice are phenotypically activated and retain their suppressive capacity. The accumulation of effector and regulatory T cells is not due to enhanced differentiation of naive T cells, but is a direct result of increased proliferation. Functional consequences of increased numbers of both regulatory and effector T cells were tested in an autoimmune model and show that GITR stimulation is protective, as it significantly delays disease induction. These data indicate that GITR regulates the balance between regulatory and effector CD4(+) T cells by enhancing proliferation of both populations in parallel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494272     DOI: 10.4049/jimmunol.0802751

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Authors:  Saravana K Kanagavelu; Victoria Snarsky; James M Termini; Sachin Gupta; Suzanne Barzee; Jacqueline A Wright; Wasif N Khan; Richard S Kornbluth; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Matthew S Tsai; Jackie Chirinos; Vadim V Deyev; Louis Gonzalez; Thomas R Malek; Robert B Levy; Eckhard R Podack
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

Review 3.  Harnessing regulatory T cells to suppress asthma: from potential to therapy.

Authors:  Alison N Thorburn; Philip M Hansbro
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-22       Impact factor: 6.914

4.  A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand.

Authors:  Avijit Ray; Sreemanti Basu; Calvin B Williams; Nita H Salzman; Bonnie N Dittel
Journal:  J Immunol       Date:  2012-02-24       Impact factor: 5.422

5.  Peritoneal T lymphocyte regulation by macrophages.

Authors:  G Composto; D Gonzalez; A Bucknum; D Silberman; J Taylor; M Kozlowski; T Bloomfield; T Bartlett; J Riggs
Journal:  Immunobiology       Date:  2010-04-10       Impact factor: 3.144

Review 6.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

7.  High viral burden restricts short-lived effector cell number at late times postinfection through increased natural regulatory T cell expansion.

Authors:  Samuel Amoah; Beth C Holbrook; Rama D Yammani; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

8.  Potential regulatory role of in vitro-expanded Vδ1 T cells from human peripheral blood.

Authors:  Fang Hua; Ning Kang; Yun-An Gao; Lian-Xian Cui; De-Nian Ba; Wei He
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

9.  OX40 is required for regulatory T cell-mediated control of colitis.

Authors:  Thibault Griseri; Mark Asquith; Claire Thompson; Fiona Powrie
Journal:  J Exp Med       Date:  2010-04-05       Impact factor: 14.307

10.  Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.

Authors:  Chen Wang; Tai Yi; Lingfeng Qin; Roberto A Maldonado; Ulrich H von Andrian; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Clin Invest       Date:  2013-03-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.